BODI
The Beachbody Company, Inc.
BODI trails on the overall score without a compensating advantage in the available component scores.
META
Meta Platforms, Inc.
META has the edge over BODI overall, supported by lower modeled downside and stronger valuation.
BODI Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Under pressure | |
| Strong |
BODI's profitability and balance sheet are currently healthy, but its revenue and cash flow are under pressure.
META Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
META's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
BODI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 2.1x | $3.25 | — |
| Cheap | 2.6x | $4.11 | +27% |
| Fair | 4.1x | $6.41 | +97% |
| Expensive | 15x | $22.97 | +607% |
Historical ranges are pointers, not guarantees.
BODI has the edge over META in the historical PE scenario, which offers more potential upside but is not a forecast.
META PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $624 | — |
| Cheap | 21x | $613 | -1.7% |
| Current | 21x | $624 | — |
| Fair | 27x | $803 | +29% |
| Expensive | 32x | $934 | +50% |
Historical ranges are pointers, not guarantees.
META's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
BODI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| Improving | |
| Limited | |
| Low |
Analysts expect BODI's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
META Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for META, but weaker profitability. However, they disagree widely on these estimates.
BODI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.56 | +$7.81 |
| Q2 2026 | $1.69 | +$10.20 |
| Q1 2026 | $0.73 | +$9.98 |
| Q4 2025 | -$0.41 | +$10.10 |
| Q3 2025 | -$6.25 | +$9.66 |
| Q2 2025 | -$8.51 | +$11.15 |
| Q1 2025 | -$9.25 | +$12.82 |
| Q4 2024 | -$10.51 | +$13.96 |
BODI has the edge over META on earnings, with more consistent year-over-year improvement.
META Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $32.16 | +9.7% |
| Q3 2026 | $29.32 | +30% |
| Q2 2026 | $26.54 | -3.7% |
| Q1 2026 | $27.50 | +7.5% |
| Q4 2025 | $23.49 | -1.6% |
| Q3 2025 | $22.58 | +6.5% |
| Q2 2025 | $27.56 | +41% |
| Q1 2025 | $25.58 | +47% |
| Q4 2024 | $23.86 | +60% |
META earned $29.32 per share over the past year, up 30% from the year before.
BODI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $45.2M | -25% |
| Q2 2026 | $49.6M | -22% |
| Q1 2026 | $54.3M | -25% |
| Q4 2025 | $55.5M | -36% |
| Q3 2025 | $59.9M | -41% |
| Q2 2025 | $63.9M | -42% |
| Q1 2025 | $72.4M | -40% |
| Q4 2024 | $86.4M | -27% |
BODI's revenue has slid since its 2020 peak: $45M last quarter, down 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.9% | -5.4 points |
| Q2 2026 | 3.4% | +9.6 points |
| Q1 2026 | 5.7% | +11 points |
| Q4 2025 | 15% | +53 points |
| Q3 2025 | 8.3% | +21 points |
| Q2 2025 | -6.2% | +2.4 points |
| Q1 2025 | -5.1% | +3.9 points |
| Q4 2024 | -38% | +13 points |
BODI's operating margin was 2.9% last quarter, down 5.4 points from the same quarter a year ago.
META Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $64.6B | +26% |
| Q2 2026 | $60.8B | +28% |
| Q1 2026 | $56.3B | +33% |
| Q4 2025 | $59.9B | +24% |
| Q3 2025 | $51.2B | +26% |
| Q2 2025 | $47.5B | +22% |
| Q1 2025 | $42.3B | +16% |
| Q4 2024 | $48.4B | +21% |
META has the edge over BODI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | -20 points |
| Q2 2026 | 31% | -12 points |
| Q1 2026 | 41% | -0.9 points |
| Q4 2025 | 41% | -7 points |
| Q3 2025 | 40% | -2.7 points |
| Q2 2025 | 43% | +5 points |
| Q1 2025 | 41% | +3.6 points |
| Q4 2024 | 48% | +7.4 points |
META has the edge over BODI on profitability, with a higher operating margin.
BODI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.4M | -171% |
| Q2 2026 | -$4M | -265% |
| Q1 2026 | -$1.7M | -205% |
| Q4 2025 | $4.3M | +$11.6M |
| Q3 2025 | $9M | +16881% |
| Q2 2025 | $2.4M | +$4.6M |
| Q1 2025 | $1.6M | -78% |
| Q4 2024 | -$7.3M | +$1.7M |
BODI has burned cash in most quarters: −$8M over the past year, against $6M the year before.
META Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -110% |
| Q2 2026 | $1.7B | -81% |
| Q1 2026 | $13.2B | +19% |
| Q4 2025 | $14.8B | +9.3% |
| Q3 2025 | $11.2B | -32% |
| Q2 2025 | $9B | -19% |
| Q1 2025 | $11.1B | -14% |
| Q4 2024 | $13.6B | +16% |
META has the edge over BODI on cash generation, producing positive trailing cash flow while its opponent burns cash.
BODI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -6.2% | -487K shares |
| 1 year | +5.3% | +372K shares |
| 3 years | +20% | +1.2M shares |
| 5 years | +22% | +1.3M shares |
BODI has 7M diluted shares, up 5.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
META Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +7M shares |
| 1 year | 0% | +1M shares |
| 3 years | -2.6% | -68M shares |
| 5 years | -10% | -286M shares |
| Available history | -11% | -303M shares |
META has the edge over BODI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $3.3B |
| Q2 2025 | $10.2B |
| Q1 2025 | $12.8B |
| Q4 2024 | — |
META hasn't bought back shares in the past year.
BODI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2020 | -1.0x | Net Cash |
BODI has the edge over META on leverage, with a lower net debt burden relative to earnings.
META Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.0x | Very low |
| Q4 2024 | -0.2x | Net Cash |
META's net debt is less than a year of its operating earnings (EBITDA).
BODI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.4 | Oversold |
| Stochastic | 2.2 | Oversold |
BODI's weekly RSI is 29 (oversold) and its Stochastic is 2 (oversold).
META Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 33.7 | Neutral |
META's weekly RSI is 48 (neutral) and its Stochastic is 34 (neutral).
BODI PE vs Communication Services Sector
| Metric | BODI | Sector median | Relative |
|---|---|---|---|
| PE | 2.1x | 16x | 87% below |
| PE % | 0 | 28 | 28 pts below |
BODI has the edge over META on valuation relative to its sector.
META PE vs Communication Services Sector
| Metric | META | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 16x | 29% above |
| PE % | 18 | 26 | 8 pts below |
META is trading at 21x earnings, a 29% premium to the Communication Services sector's median of 16x.
BODI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.31 | 25% below |
| 20 week MA | $6.65 | 51% below |
| 50 week MA | $9.06 | 64% below |
| 100 week MA | $7.32 | 56% below |
| 200 week MA | $10.8 | 70% below |
BODI is in a downtrend: it's below all five of its weekly moving averages, and 70% below its 200-week average.
META Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $674.9 | 7.6% below |
| 20 week MA | $634.5 | 1.7% below |
| 50 week MA | $630.8 | 1.1% below |
| 100 week MA | $647.8 | 3.7% below |
| 200 week MA | $517.5 | 21% above |
META has the edge over BODI on trend strength, trading above more of its moving averages.
BODI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $523.5 | $126.0 | -76% |
| 2022 | $126.0 | $27.3 | -78% |
| 2023 | $27.3 | $8.29 | -70% |
| 2024 | $8.29 | $6.07 | -27% |
| 2025 | $6.07 | $10.1 | +66% |
| 2026 YTD | $10.1 | $3.25 | -68% |
BODI has finished lower in four of the last five years. It's down 68% so far in 2026.
META Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $208.1 | $267.4 | +28% |
| 2021 | $267.4 | $335.2 | +25% |
| 2022 | $335.2 | $118.0 | -65% |
| 2023 | $118.0 | $354.0 | +200% |
| 2024 | $354.0 | $599.8 | +69% |
| 2025 | $599.8 | $663.3 | +11% |
| 2026 YTD | $663.3 | $623.6 | -6% |
META has the edge over BODI on returns for 2026, with the stronger performance.